Bausch + Lomb Gains FDA Approval of LUMIFY® Preservative Free Redness Reliever Eye Drops, Marking the 22nd FDA Approval For Butchertown Clinical Trials

Bausch + Lomb Corporation announced, during April 2024,  the U.S. Food and Drug Administration (FDA) approved LUMIFY® Preservative Free redness reliever eye drops, the first and only over-the-counter preservative-free eye drop with low-dose OTC brimonidine tartrate for the treatment of ocular redness due to minor eye irritations.

“LUMIFY Preservative Free significantly reduces redness within one minute and lasts up to eight hours," said John Ferris, executive vice president, Consumer, Bausch + Lomb.

Now available, this over-the-counter (OTC) eyedrop underwent clinical trials at Butchertown Clinical Trials, with Dr. Guruprasad R. Pattar, MD, PhD of The Eye Care Institute as the Principal Investigator.

Although OTC products do not necessarily have to undergo strict clinical trial protocols, nor is FDA approval typically required, this product did so as it contains a small quantity of a prescription medication called brimonidine tartrate, most often used to treat open angle glaucoma or ocular hypertension. In the small quantity used in Lumify PF .025%, brimonidine tartrate acts to relieve ocular redness.

With the addition of Lumify PF .025% I have the confidence to strongly recommend this OTC product to my patients seeking relief from red eyes, said Dr. Emily Ebelhar, OD, also of The Eye Care Institute, who served as Sub Investigator. This marks the 22nd FDA approval for Butchertown Clinical Trials, an affiliate of The Eye Care Institute.